ADVA
2.12.2021 09:02:10 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that BMC TV deployed its FSP 150 Carrier Ethernet technology to transport coverage of the Paralympic Games from Tokyo to London. The robust, low-power solution empowered BMC TV to cost-effectively provide highly reliable services, enabling hundreds of hours of live broadcasting on high-definition television and online streams. The close support of ADVA’s team, together with the ease of use of its FSP 150 device, helped to ensure the success of the project. Fiber optic solutions provider Fibre Technologies also played a key role.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005059/en/
“We’re proud to have helped bring high-quality coverage of the Paralympics to a UK audience of over 20 million. By harnessing ADVA’s edge Ethernet equipment, we were able to maintain superb network uptime and ensure an exceptional viewer experience,” said Tim Horsfield, director, BMC TV. “We were very impressed with how straightforward ADVA’s solution was to deploy. It also simplifies operations by using established OAM procedures, while its fanless design and low power consumption help to minimize carbon footprint. What’s more, ADVA’s team was always on hand to lend their support and expertise.”
Using the ADVA FSP 150-XG108 Series of Layer 2 service demarcation and aggregation devices, BMC TV was able to provide highly reliable and cost-effective broadcast services. This allowed Channel 4, one of Britain’s biggest television networks, to deliver a rich and immersive viewing experience with every sport at the Tokyo 2020 Paralympic Games covered live and in full. The ADVA FSP 150-XG108 Series enabled BMC TV to efficiently aggregate 1Gbit/s services into 10Gbit/s wavelengths. With its small footprint, redundant power supply and hardware-assisted synchronization, the solution is optimized for cost-sensitive high-bandwidth edge applications.
“The Tokyo Paralympics entertained and inspired millions of viewers. That’s why enabling BMC TV to transmit comprehensive coverage of the games was so rewarding for our team. Our technology and support were key to making this project a major success,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our solution offers advanced demarcation and aggregation capabilities alongside a rich feature set, including hardware-assisted synchronization and zero-touch provisioning for quick and easy service activation. Once again, our FSP 150 technology has shown itself to be in a class of its own for fast and seamless deployment of cost-sensitive Carrier Ethernet services.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About BMC TV
BMC TV are Media Moving experts™. Specialists in IP transport of Broadcast Media over Fibre, Satellite and the Cloud. BMC TV helps broadcasters with connectivity solutions for sports, news and broadcast special events and to deliver this content in multiple formats, to multiple destinations, all around the world. www.bmcuk.tv .
About FTL
Fibre Technologies Ltd (FTL) based in Berkshire, are a highly accredited, multi division, solutions integrator, who specialise in providing the best possible solutions using the latest technology from their chosen partners. They are a financially independent company with a customer base spanning Telco’s, ISP’s, MSP’s, Mod/Government, Education, Industrial and enterprise clients. www.fibre.co.uk .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005059/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom